"These mechanisms collectively may reduce the risk of cognitive decline, particularly in diabetic patients, and warrant ...

Scientists found a 22 percent lower risk of any dementia and Parkinson's among a group taking SGLT2 inhibitors for type 2 ...

Researchers have found that people who take a type of type 2 diabetes drugs SGLT2 inhibitors have a significantly lower risk ...

In patients older than 40 years, the type 2 diabetes drug class showed increased benefits over DPP-4 inhibitors at reducing ...

A Korean study published recently suggests people with type 2 diabetes who are prescribed a particular class of drug might be ...

According to a new study, certain diabetes medications may significantly reduce this risk. These drugs, called gliflozins or ...

Like other drugs for heart failure, SGLT2 inhibitors were originally developed to lower blood sugar levels in patients with diabetes. But this drug soon found its way into the heart of clinics that ...

Taking SGLT-2 inhibitors was associated with a 35% lower risk of developing dementia compared with taking another common diabetes drug with a different mechanism. Although the authors call for ...

New findings add to the pile of research on the possible neuroprotective effects of drugs like dapagliflozin, empagliflozin, and dulaglutide for patients with type 2 diabetes. New research ...

With this mechanism, researchers can expect more reliable and precise data, which is critical for advancing their understanding of particle physics. The research team is optimistic about the ...

The researchers found that during a median follow-up of 4.4 years, the primary outcome event of presumed clinical onset of dementia occurred in 69 and 43 participants in the SGLT2 and dulaglutide ...